Skip to main content
Log in

Activity of C1 esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Summary

Vascular-leak syndrome (VLS) is a common complication in the first 3 weeks after bone marrow transplantation (BMT). The patients present with weight gain, generalized edema, ascites, pericardial or pleural effusions, tachycardia, arterial hypotonia, and/ or pre-renal failure. The aim of our study was to investigate the role of the complement system in VLS. The protein concentrations of C3 and C4 were studied by immunodiffusion, and total hemolytic complement activity was studied by assessment of CH50. C1 esterase inhibitor (C1 Inh), the major inhibitor of the classical pathway of complement, was assessed by a functional test. Activation of complement was assessed by C4d (a C4 activation product). Twelve patients were followed prospectively from start of conditioning therapy to day +21 after bone marrow transplantation. Eight of 12 patients did not develop VLS. These patients had an increase of C3 between day +9 and day +13 (range: 1.3- to 1.5-fold, median: 1.4-fold), C4 (range: 1.3- to 1.9-fold, median: 1.4-fold), CH50 (range: 1.3- to 1.6-fold, median: 1.4-fold), and C1 Inh (range: 1.2- to 1.5-fold, median: 1.3-fold). Four of 12 patients developed VLS. C1 Inh activity was decreased to 0.60- to 0.80-fold. This decrease began 2–6 days prior to clinical diagnosis of VLS (n=3), or at onset of VLS (n=1). Patients with VLS showed elevated C4d concentrations (up to 2.4 mg/dl, upper normal treshold value: 0.9 mg/dl). Patients with VLS reveal an activated state of the complement system which is accompanied by a reduced activity of C1 Inh. Insufficient control of complement activation may contribute to VLS in patients after BMT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

BMT:

bone marrow transplantation

VLS:

vascular leak syndrome

BW:

body weight

C1 Inh:

C1 esterase inhibitor

CH50:

total hemolytic complement

C3:

third component of complement

C4:

fourth component of complement

C4d:

C4 activation product

References

  1. Agostini A de, Lijnen HR, Pixley RA, Colman RW, Schapira M (1984) Inactivation of factor XII active fragment in normal plasma-predominant role of C1-inhibitor. J Clin Invest 73:1542–1549

    Google Scholar 

  2. Atkinson JP, Waldmann TA, Stein SF, Gelfand JA, McDonald JW, Heck LW, Cohen EL, Kaplan AP, Frank MM (1977) Systemic capillary leak syndrome and monoclonal gammopathy. Medicine (Baltimore) 56:225–239

    Google Scholar 

  3. Blume KG, Forman SJ, O'Donnell MR, Doroshow JH, Krance RA, Nademanee AP, Snyder DS, Schmidt GM, Fahey JL, Metter GE, Hill LR, Findley DO, Sniecinski IJ (1987) Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematological malignancies. Blood 69:1015–1020

    Google Scholar 

  4. Bork K, Witzke G (1989) Long-term prophylaxis with C1 inhibitor concentrate in patients with recurrent angioedema caused by hereditary and acquired C1 inhibitor deficiency. J Allergy Clin Immunol 83:677–682

    Google Scholar 

  5. Brower MS, Harpel PC (1982) Proteolytic cleavage and inactivation of alpha-2-plasmin-inhibitor and C1 inactivator by human polymorphonuclear leucocyte elastase. J Biol Chem 257:9849–9854

    Google Scholar 

  6. Burdach S (1991) The granulocyte/macrophage-colony-stimulating factor (GM-CSF): basic science and clinical application. Klin Padiatr 203:302–310

    Google Scholar 

  7. Burdach St, Peters C, Paulussen M, Nürnberger W, Wurm R, Wernet P, Dilloo D, Voehringer R, Gadner H, Göbel U, Jürgens H (1991) Improved relapse-free survival in patients with poor-prognosis Ewing's sarcoma after consolidation with hyperfractionated total body irradiation and fractionated high-dose melphalan followed by high-dose etoposide and hematopoietic rescue. Bone Marrow Tranplant 7 [Suppl 2]:95

    Google Scholar 

  8. Ghebrehiwet B, Randazzo BR, Dunn JT, Silverberg M, Kaplan AP (1983) Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 71:1450–1456

    Google Scholar 

  9. Gluckman E, Barrett AJ, Arcese W, Devergie A, Degoulet P (1981) Bone marrow transplantation in severe aplastic anemia: a survey of the European Group for Bone Marrow Transplantation (EGBMT). Br J Haematol 49:165–176

    Google Scholar 

  10. Hack CE, Nuijens JH, Felt-Bersma RJF, Schreuder WO, Ehrenberg-Belmer AJM, Paardekooper J, Bronsveld W, Thijs LG (1989) Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 86:20–26

    Google Scholar 

  11. Hack CE, Wagstaff J, Strack van Schijndel RJM, Ehrenberg AJM, Pinedo HM, Thijs LG, Nuijens JH (1991) Studies of the contact system of coagulation during therapy with high doses of recombinant IL-2: implications for septic shock. Thromb Haemost 65:497–503

    Google Scholar 

  12. Heber H, Kolde HJ, Heimburger N, Svendsen G (1983) A chromogenic substrate assay for Cl-inhibitor. Thromb Haemost 50:227–230

    Google Scholar 

  13. Killeen AA, Meyer KC, Vogt JM, Edson JR (1987) Kallikrein inhibition and C1 esterase inhibitor levels in patients with the lupus inhibitor. Am J Clin Pathol 88:223–228

    Google Scholar 

  14. Lint TF (1982) Laboratory detection of complement activation and complement deficiencies. Am J Med Technol 48:743–748

    Google Scholar 

  15. Mammen EF (1990) Contact activation: the interaction of clotting, fibrinolytic, kinin and complement systems. Biomed Prog 2:31–34

    Google Scholar 

  16. Nürnberger W, Stannigel H, Müntel V, Michelmann I, Wahn V, Göbel U (1990) In vivo activation of the fourth component of the complement system (C4) in premature and term infants with generalized bacterial infection. Klin Padiatr 202:141–146

    Google Scholar 

  17. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 137:1735–1738

    Google Scholar 

  18. Schapira M, Scott CF, Colman RW (1982) Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 426–466

  19. Schapira M, de Agostini A, Schifferli JA, Colman RW (1985) Biochemistry and pathophysiology of human C1 inhibitor: current issues. Complement 2:111–126

    Google Scholar 

  20. Späth PJ, Baumgartner C, Gratwohl A, Doran JE, Elisa A, Bachmann P, Scherz R, Berger C, Morell A, Tichelli A, Speck B (1989) Complement and humoral immune response in bone marrow transplant recipients: effects of intravenous immunoglobulin administration. Transplant Proc 21/1:3064–3066

    Google Scholar 

  21. Spitzer TR, Cottier-Fox M, Torrisi J, Cahill R, Greenspan A, Lynch M, Deeg HJ (1989) Escalating doses of etoposide with cyclophosphamide and fractional total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transplant 4:559–566

    Google Scholar 

  22. Thijs LG, Hack CE, Strack van Schijndel RJM, Nuijens JH, Wolbink GJ, Ehrenberg AJM, van der Vail H, Wagstaff J (1990) Activation of complement system during immunotherapy with recombinant IL-2. J Immunol 144:2419–2424

    Google Scholar 

  23. Vachino G, Gelfand JA, Atkins MB, Tamerius JD, Demchak P, Meir JW (1991) Complement activation in cancer patients undergoing immunotherapy with interleukin-2: binding of complement and C-reactive protein by IL-2-activated lymphocytes. Blood 78:2505–2513

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

This work was supported by theElterninitiative Kinderkrebs-klinik e.V., Düsseldorf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nürnberger, W., Michelmann, I., Petrik, K. et al. Activity of C1 esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation. Ann Hematol 67, 17–21 (1993). https://doi.org/10.1007/BF01709661

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01709661

Key words

Navigation